All In Biotech

Drug Trial Radar · NCT04944979

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 31, 2021

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Kedrion S.p.A.Industry
Sponsor type
Industry
First posted
Jun 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).

Conditions

  • Primary Immunodeficiency Disease

Interventions

  • Kedrion IVIG 10%Biological

    Kedrion intravenous immunoglobulin (IVIg) 10%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of Acute Serious Bacterial InfectionsTime frame: From Baseline (Day 1) up to week 51/52

Locations

21 sites in 6 countries. Site status is shown where the registry gives one.

  • Benioff Children's Hospital - Mission Bay

    San Francisco, California

  • IMMUNOe Health and Research Centers

    Centennial, Colorado

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida

  • Velocity Clinical Research - MedPharmics - Lafayette

    Lafayette, Louisiana

  • Louisiana State University Shreveport

    Shreveport, Louisiana

  • Duke Children's Hospital & Health Center

    Durham, North Carolina

  • Asthma and Allergy Center - Toledo

    Toledo, Ohio

  • Vital Prospects Clinical Research Institute PC

    Tulsa, Oklahoma

  • Dél-Pesti Centrumkórház - Országos Hematológiai És Infektológiai Intézet

    Budapest, Hungary

  • SST Spedali Civili di Brescia

    Brescia, Italy

  • Azienda Ospedaliero-Universitaria - Ospedale Pediatrico Meyer

    Florence, Italy

  • I.R.C.C.S. Istituto Giannina Gaslini

    Genova, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinic

    Milan, Italy

  • Azienda Ospedaliera Universitaria "Federico II"

    Naples, Italy

  • Fondazione Policlinico Tor Vergata

    Roma, Italy

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • Centro Hospitalar Lisboa Central - Hospital Dona Estefânia

    Lisbon, Portugal

  • Centro Hospitalar Universitário do Porto - Hospital Santo António

    Porto, Portugal

  • Children's City Clinical Hospital No. 9 named after G.N. Speransky, Moscow City Health Department

    Moscow, Russia

  • Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology

    Moscow, Russia

  • Národný ústav detských chorôb (National Institute of Pediatric Diseases)

    Bratislava, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.